Sailish Honap1,2, Susanna Meade3, Hajir Ibraheim4, Peter M Irving3,5, Michael P Jones6, Mark A Samaan3. 1. IBD Centre, 1st Floor IBD Centre, Westminster Bridge Road, St Thomas Hospital, Guys and St Thomas NHS Foundation Trust, London, SE1 7EH, UK. shonap@nhs.net. 2. School of Immunology and Microbial Sciences, Kings College London, London, UK. shonap@nhs.net. 3. IBD Centre, 1st Floor IBD Centre, Westminster Bridge Road, St Thomas Hospital, Guys and St Thomas NHS Foundation Trust, London, SE1 7EH, UK. 4. Department of Metabolism, Digestion and Reproduction, Norfolk Place, St Marys Campus, Imperial College London, London, W2 1PG, UK. 5. School of Immunology and Microbial Sciences, Kings College London, London, UK. 6. Center for Emotional Health, Department of Psychology, Macquarie University, New South Wales, NSW, 2109, Australia.
Abstract
INTRODUCTION: Ustekinumab, an interleukin-12 and interleukin-23 antagonist, is licensed for the treatment of Crohn's disease (CD) and ulcerative colitis (UC) after the phase III trial programs demonstrated efficacy over placebo. However, these findings may not be directly transferable to the real-world due to the stringent inclusion criteria of clinical trials. METHODS: We conducted a systematic review and meta-analysis of the safety and effectiveness of ustekinumab in inflammatory bowel disease (IBD). A systematic literature search was conducted via Medline and Embase from inception to April 21, 2020. Observational studies assessing ustekinumab's safety and effectiveness by reporting response, remission and/or adverse events (AE) in either CD or UC were included. Two reviewers independently assessed risk of bias and extracted study data. Random-effects meta-analysis was performed to pool rates of clinical response, remission, and safety data. RESULTS: Following deduplication, 2147 records were identified of which 41 studies (38 CD, 3 UC) comprising 4400 patients were included for quantitative analysis. Pooled clinical remission rates for CD were 34% (95% CI, 26%-42%) following induction and 31% (95% CI, 25%-38%) at one year. For UC, post-induction clinical remission rates were 39% (95% CI, 23%-56%). Serious AEs were reported in 5.6% of patients. Pregnancy outcomes were similar to the general population. One-third of patients with active baseline perianal disease responded or had fistula healing with ustekinumab. CONCLUSIONS: In the most comprehensive systematic review and meta-analysis to date, and the first to include UC, ustekinumab was shown to be effective and safe in the real-world treatment of IBD.
INTRODUCTION: Ustekinumab, an interleukin-12 and interleukin-23 antagonist, is licensed for the treatment of Crohn's disease (CD) and ulcerative colitis (UC) after the phase III trial programs demonstrated efficacy over placebo. However, these findings may not be directly transferable to the real-world due to the stringent inclusion criteria of clinical trials. METHODS: We conducted a systematic review and meta-analysis of the safety and effectiveness of ustekinumab in inflammatory bowel disease (IBD). A systematic literature search was conducted via Medline and Embase from inception to April 21, 2020. Observational studies assessing ustekinumab's safety and effectiveness by reporting response, remission and/or adverse events (AE) in either CD or UC were included. Two reviewers independently assessed risk of bias and extracted study data. Random-effects meta-analysis was performed to pool rates of clinical response, remission, and safety data. RESULTS: Following deduplication, 2147 records were identified of which 41 studies (38 CD, 3 UC) comprising 4400 patients were included for quantitative analysis. Pooled clinical remission rates for CD were 34% (95% CI, 26%-42%) following induction and 31% (95% CI, 25%-38%) at one year. For UC, post-induction clinical remission rates were 39% (95% CI, 23%-56%). Serious AEs were reported in 5.6% of patients. Pregnancy outcomes were similar to the general population. One-third of patients with active baseline perianal disease responded or had fistula healing with ustekinumab. CONCLUSIONS: In the most comprehensive systematic review and meta-analysis to date, and the first to include UC, ustekinumab was shown to be effective and safe in the real-world treatment of IBD.
Authors: P Wils; Y Bouhnik; P Michetti; B Flourie; H Brixi; A Bourrier; M Allez; B Duclos; M Serrero; A Buisson; A Amiot; M Fumery; X Roblin; L Peyrin-Biroulet; J Filippi; G Bouguen; V Abitbol; B Coffin; M Simon; D Laharie; B Pariente Journal: Aliment Pharmacol Ther Date: 2018-01-08 Impact factor: 8.171
Authors: Bruce E Sands; William J Sandborn; Remo Panaccione; Christopher D O'Brien; Hongyan Zhang; Jewel Johanns; Omoniyi J Adedokun; Katherine Li; Laurent Peyrin-Biroulet; Gert Van Assche; Silvio Danese; Stephan Targan; Maria T Abreu; Tadakazu Hisamatsu; Philippe Szapary; Colleen Marano Journal: N Engl J Med Date: 2019-09-26 Impact factor: 91.245
Authors: Bram Verstockt; Erwin Dreesen; Maja Noman; An Outtier; Nathalie Van den Berghe; Isolde Aerden; Griet Compernolle; Gert Van Assche; Ann Gils; Séverine Vermeire; Marc Ferrante Journal: J Crohns Colitis Date: 2019-07-25 Impact factor: 9.071
Authors: C Ma; R N Fedorak; G G Kaplan; L A Dieleman; S M Devlin; N Stern; K I Kroeker; C H Seow; Y Leung; K L Novak; B P Halloran; V W Huang; K Wong; P K Blustein; S Ghosh; R Panaccione Journal: Aliment Pharmacol Ther Date: 2017-03-02 Impact factor: 8.171
Authors: Brian G Feagan; William J Sandborn; Christopher Gasink; Douglas Jacobstein; Yinghua Lang; Joshua R Friedman; Marion A Blank; Jewel Johanns; Long-Long Gao; Ye Miao; Omoniyi J Adedokun; Bruce E Sands; Stephen B Hanauer; Severine Vermeire; Stephan Targan; Subrata Ghosh; Willem J de Villiers; Jean-Frédéric Colombel; Zsolt Tulassay; Ursula Seidler; Bruce A Salzberg; Pierre Desreumaux; Scott D Lee; Edward V Loftus; Levinus A Dieleman; Seymour Katz; Paul Rutgeerts Journal: N Engl J Med Date: 2016-11-17 Impact factor: 91.245
Authors: Vince B C Biemans; Andrea E van der Meulen-de Jong; Christine J van der Woude; Mark Löwenberg; Gerard Dijkstra; Bas Oldenburg; Nanne K H de Boer; Sander van der Marel; Alexander G L Bodelier; Jeroen M Jansen; Jeoffrey J L Haans; Rosaline Theeuwen; Dirk de Jong; Marie J Pierik; Frank Hoentjen Journal: J Crohns Colitis Date: 2020-01-01 Impact factor: 9.071
Authors: Aditi Kumar; Alexander Cole; Jonathan Segal; Philip Smith; Jimmy K Limdi Journal: Therap Adv Gastroenterol Date: 2022-02-17 Impact factor: 4.409
Authors: Joanneke E Jansen; Dominik Aschenbrenner; Holm H Uhlig; Mark C Coles; Eamonn A Gaffney Journal: PLoS Comput Biol Date: 2022-06-22 Impact factor: 4.779
Authors: Sailish Honap; Lulia Al-Hillawi; Samantha Baillie; Aaron Bancil; Lawrence Matini; Rebecca Lau; Klaartje Bel Kok; Kamal Patel; Alissa Walsh; Peter M Irving; Mark A Samaan Journal: Frontline Gastroenterol Date: 2022-04-28